Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ALNY exchanges : Nasdaq save search
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -1.17%
H: 1.01%
C: 0.11%
first conference financial results
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Published: 2024-03-20 (Crawled : 13:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.11%
H: 0.43%
C: -0.01%
cardiology results study
Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.33%
H: 1.88%
C: 0.84%
therapeutics
Zenas BioPharma Appoints Patricia Allen to its Board of Directors
Published: 2024-03-06 (Crawled : 16:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.31%
H: 0.06%
C: -0.33%
biopharma
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Published: 2024-03-05 (Crawled : 15:30) - biospace.com/
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.09%
H: 2.06%
C: -2.68%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
hepatitis trial
Alnylam to Webcast Presentations at Upcoming March Investor Conferences - February 27, 2024
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.84%
H: 0.82%
C: -0.63%
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-22 (Crawled : 00:00) - biospace.com/
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: -0.87%
H: 2.89%
C: 2.14%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.69%
H: 2.99%
C: 2.59%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.17%
H: 6.18%
C: 5.4%
year update financial results
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Published: 2024-02-15 (Crawled : 14:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -8.62%
H: 2.18%
C: -1.71%
year pharmaceuticals financial results
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
TSVT | $4.28 -7.56% -8.18% 470K
|
|
| O: -1.16%
H: 9.94%
C: 2.34%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -1.23%
H: 1.0%
C: 0.17%
year financial results
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-01-29 (Crawled : 14:30) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.27%
H: 1.32%
C: 1.02%
conference year financial results
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
MDGL | $204.51 -6.35% -6.78% 580K
|
Health Technology
|
| O: 1.29%
H: 0.35%
C: -3.04%
HEPA | $1.39 -6.71% -7.19% 37K
|
Health Technology
|
| O: -0.48%
H: 7.69%
C: 1.44%
ALT | $7.095 -6.28% -6.69% 2.2M
|
Commercial Services
|
| O: -0.8%
H: 6.02%
C: 0.6%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.46%
H: 3.04%
C: 2.67%
ETNB | $8.59 -3.7% -3.84% 870K
|
Health Technology
|
| O: 1.19%
H: 0.63%
C: -0.72%
liver disease companies key growth market
Opinion: Brain Health Matters; We Must Not Lose Momentum
Published: 2024-01-08 (Crawled : 07:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.05%
H: 4.12%
C: 3.98%
health momentum
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 13:30) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.8%
H: 3.23%
C: 2.66%
conference presentation
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
Published: 2023-12-13 (Crawled : 14:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.14%
H: 4.22%
C: 3.97%
day innovation pipeline platform
Alnylam to Webcast Virtual R&D Day - December 6, 2023
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.37%
H: 3.09%
C: 2.35%
day
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.93%
H: 2.49%
C: 1.64%
work
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 1.02%
H: 4.5%
C: 3.38%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.04%
H: 1.92%
C: 1.89%
meeting hepatitis liver ongoing trials today
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 15:00) - biospace.com/
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 0.98%
H: 7.06%
C: 6.93%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.49%
H: 0.74%
C: -2.08%
meeting hepatitis liver ongoing trials
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.